NCT04286412View on ClinicalTrials.gov

Nonacog Alfa Prophylaxis And Treatment Of Bleeding Episodes In Previously Treated Patients With Hemophilia B

PHASE4CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

February 10, 2020

Primary Completion Date

September 24, 2020

Study Completion Date

September 24, 2020

Conditions
Hemophilia B
Interventions
BIOLOGICAL

Nonacog alfa

Nonacog alfa is indicated in India for the treatment and prophylaxis of bleeding in patients with hemophilia B (congenital factor IX deficiency).

Trial Locations (5)

141008

Christian Medical College and Hospital, Ludhiana

395002

Nirmal Hospital Pvt Ltd., Surat

400022

K.J. Somaiya Hospital and Research Centre, Mumbai

411004

Sahyadri Clinical Research & Development Centre, Pune

Sahyadri Super Specialty Hospital, Pune

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04286412 - Nonacog Alfa Prophylaxis And Treatment Of Bleeding Episodes In Previously Treated Patients With Hemophilia B | Biotech Hunter | Biotech Hunter